Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.
Inflammation Expert Opinions Philippe Gabriel Steg reflects on the CANTOS trial results that confirm the long-standing hypothesis that inflammation plays a role in CV events and he considers which questions remain to be answered before broad clinical application of this concept.
Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.
ESC 2017 One of the Grand Debates of course focused on different interpretations of the CANTOS trial data. Paul Ridker and Alberico Catapano debated how central inflammation is to CVD.
ESC 2017 Peter Libby, who started basic research on the role of IL-1 in atherogenesis 30 years ago, gives his perspective on the CANTOS results, including the preliminary results that hint at a reduction in cancer fatalities.
ESC 2017 Paul Ridker shares what the results of the CANTOS trial mean to him as a clinician. Lowering inflammation by inhibiting IL-1β with canakinumab reduced CV events in aggressively treated CV patients.
ESC 2017 Inhibition of IL-1β with canakinumab significantly lowered hsCRP levels and CV events, especially in those with higher than median CRP reduction, and incident lung cancer and lung cancer mortality were reduced.
Anti-PCSK9 vaccination (AT04A) lowers LDL-c, atherosclerosis and inflammatory markers in mouse model for atherosclerosis. Phase I study into this vaccine has started
The phase III CANTOS study shows ACZ885 (canakinumab), in addition to standard care, reduces CV events in people with prior myocardial infarction and inflammatory atherosclerosis.
High frequency and long duration of tooth brushing were associated with a better endothelial function, implying that adequate tooth brushing may contribute to the prevention of CV events.
In addition to improving the lipoprotein and inflammatory profile, in vitro and in vivo experiments, as well as protein profiling of patient samples showed RVX-208 modulates the complement cascade.
VBWG ACC 2017 HIV-infected persons have increased CV risk. Even when HIV is adequately suppressed, chronic inflammation persists. Studying this condition can give insights in how to reduce CV risk and possibly HIV infection in these individuals.
RG7652, a PCSK9 antibody, dose-dependently reduced LDL-c, ApoB and Lp(a), but not inflammatory proteins, without concerning adverse events.